Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease
This article was originally published in The Pink Sheet Daily
The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.
You may also be interested in...
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.
The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.
Britain’s charitable foundation The Wellcome Trust has formally launched a £200 million ($325 million) fund that will invest in both early and growth-stage companies, taking a long-term view and focused initially on opportunities in the UK, Europe and on the U.S East Coast.